Five-year Patient-level Meta-analysis of ILLUMENATE EU RCT and Pivotal Study Results Confirms Safety Profile of Philips Stellarex .035” Low-dose Drug-Coated Balloon

Amsterdam, the Netherlands, April 20 (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the five-year patient-level meta-analysis of two major randomized controlled trials (RCTs). The findings, which represent the highest level of the evidence pyramid [1], confirm the long-term safety of the Philips Stellarex Drug-Coated Balloon (DCB). The [...]

Five-year ILLUMENATE EU RCT and Pivotal Study Results Confirm Safety Profile of Philips Stellarex .035” Low-dose Drug-coated Balloon

Amsterdam, the Netherlands, Jan. 25 (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the final, five-year results of two major randomized controlled trials (RCTs) that show no difference in all-cause mortality between patients treated with the Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current [...]

Four-year Results from Patient-level Meta-analysis Confirm Safety Profile of Philips Stellarex .035” Low-dose Drug-coated Balloon

Amsterdam, the Netherlands, Nov. 7 (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the results of a patient-level meta-analysis that confirms the safety profile of its Stellarex drug-coated balloon (DCB) at four years. Including data from two major randomized controlled trials (RCTs), the results show no difference in mortality [...]

Philips Introduces New 200mm and 150mm Stellarex 0.035” Low-dose Drug-coated Balloons to Broaden Treatment Options for Peripheral Artery Disease Patients

Amsterdam, the Netherlands, Oct. 15 (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced two new balloons to its Stellarex 0.035” low-dose drug-coated balloon (DCB) portfolio. The new 200mm and 150mm Stellarex 0.035” low-dose DCBs have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of [...]

Third-party Evaluation Confirms Safety Profile of Philips Stellarex .035″ Low-dose Drug-coated Balloon

Amsterdam, the Netherlands, Oct. 1 (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the results of third-party analyses of patient-level data from worldwide clinical trials of the Philips Stellarex .035″ low-dose DCB. The analyses, which were performed by US-based contract research organization Syntactx, were published today in [...]